Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Sweeney

Showing results (81-90 of 264) with videos related to

Pageof 27
Sort By:
BJU International|November 17, 2007
Novel agents for muscle-invasive and advanced urothelial cancerGuru Sonpavde, Robert Ross, Thomas Powles, et al.
Clinical & Experimental Metastasis|June 25, 2018
Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolideKatherine L Morel, Rebecca J Ormsby, Emma L Solly, et al.
Cancer|January 30, 2002
Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumorLiang Cheng, Jian Gu, Thomas M Ulbright, et al.
International Journal of Cancer|July 30, 2010
A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen speciesRajasubramaniam Shanmugam, Praveen Kusumanchi, Hitesh Appaiah, et al.
JNCI Cancer Spectrum|July 31, 2019
A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analysesWanling Xie, Susan Halabi, Jayne F Tierney, et al.
Cancer|October 18, 2007
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancerGuru Sonpavde, Kim N Chi, Thomas Powles, et al.
Pancreas|September 26, 2008
Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancerMichele T Yip-Schneider, Huangbing Wu, Victor Njoku, et al.
European Urology|May 18, 2024
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate CancerSabine D Brookman-May, Marc Buyse, Stephen J Freedland, et al.
BJU International|December 12, 2018
Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and GermanyJohn Withington, Alexander P Cole, Christian P Meyer, et al.
Translational Oncology|June 10, 2015
[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue CompartmentsKeisha C McCall, Su-Chun Cheng, Ying Huang, et al.
Pageof 27

Showing results (81-90 of 264) with videos related to

Sort By:
Pageof 27
BJU International|November 17, 2007
Novel agents for muscle-invasive and advanced urothelial cancerGuru Sonpavde, Robert Ross, Thomas Powles, et al.
Clinical & Experimental Metastasis|June 25, 2018
Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolideKatherine L Morel, Rebecca J Ormsby, Emma L Solly, et al.
Cancer|January 30, 2002
Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumorLiang Cheng, Jian Gu, Thomas M Ulbright, et al.
International Journal of Cancer|July 30, 2010
A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen speciesRajasubramaniam Shanmugam, Praveen Kusumanchi, Hitesh Appaiah, et al.
JNCI Cancer Spectrum|July 31, 2019
A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analysesWanling Xie, Susan Halabi, Jayne F Tierney, et al.
Cancer|October 18, 2007
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancerGuru Sonpavde, Kim N Chi, Thomas Powles, et al.
Pancreas|September 26, 2008
Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancerMichele T Yip-Schneider, Huangbing Wu, Victor Njoku, et al.
European Urology|May 18, 2024
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate CancerSabine D Brookman-May, Marc Buyse, Stephen J Freedland, et al.
BJU International|December 12, 2018
Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and GermanyJohn Withington, Alexander P Cole, Christian P Meyer, et al.
Translational Oncology|June 10, 2015
[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue CompartmentsKeisha C McCall, Su-Chun Cheng, Ying Huang, et al.
Pageof 27